The Canadian Cancer Trials Group Central Operations and Statistics Centre will be closed on Monday, February 19, 2018 for Family Day. Regular business hours will resume on Tuesday, February 20 at 8:30 am EDT.
CCTG trials closed to accrual
Wednesday, November 1, 2017
GAC.1 trial: Phase III Randomized Study of Adjuvant Chemoradiation After Resection in Patients with Gastric or Gastroesophageal Adenocarcinoma, has been permanently closed by the lead group.
The purpose of the trial to determine whether overall survival is prolonged in patients with resected gastric adenocarcinoma who receive epirubicin, cisplatin and infusional 5-FU (ECF) before and after infusional 5-FU plus radiotherapy (RT) when compared to those treated with bolus 5-FU and leucovorin before and after infusional 5-FU plus RT. Phase III Randomized Study of Adjuvant Chemoradiation After Resection in Patients with Gastric or Gastroesophageal Adenocarcinoma.
Primary publication: GAC.1
Fuchs CS, Niedzwiecki D, Mamon HJ, Tepper JE, Ye X, Swanson RS, Enzinger PC, Haller DG, Dragovich T, Alberts SR, Bjarnason GA, Willett CG, Gunderson LL, Goldberg RM, Venook AP, Ilson D, O'Reilly E, Ciombor K, Berg DJ, Meyerhardt J, Mayer RJ. Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance) (ONLINE). J Clin Oncol JCO, 2017. http://ascopubs.org/doi/full/10.1200/JCO.2017.74.2130